Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is making significant advancements in the biopharmaceutical sector with its lead asset, deucrictibant, which shows promising potential based on comprehensive Phase 2 study data and upcoming pivotal Phase 3 trials for both treatment and prevention of HAE attacks. The company's updated global peak sales estimate for deucrictibant has increased to $1.65 billion by 2037 due to its strong performance in improving patients' quality of life, with 100% of participants achieving "well-controlled HAE" status and reporting health-related quality of life improvements. Furthermore, given the estimated prevalence of HAE and the lack of approved therapies in this space, deucrictibant is well-positioned to capture substantial market share, bolstered by data indicating it may serve as a best-in-class oral rescue therapy.

Pharvaris NV faces significant challenges due to the inadequate de-risking of bradykinin B2 receptor antagonism in the chronic prophylaxis setting, which raises concerns about the viability of its therapeutic approach. The highly competitive market for hereditary angioedema (HAE) treatments is dominated by established segment leaders, which could hinder Pharvaris's ability to gain traction with its novel therapy, deucrictibant. Additionally, the impending approval of multiple subcutaneous therapies over the next 36 months presents a risk of eroding Pharvaris's market share and limiting the uptake of its product, further contributing to a negative outlook for the company's stock.